Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Astellas Pharma Inc.
  6. News
  7. Summary
    4503   JP3942400007


SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Astellas Pharma : Transfers Five Legacy Products in Europe, Russia, CIS and Asia to Cheplapharm

06/16/2021 | 04:18am EDT

Press Release

Astellas Transfers Five Legacy Products

in Europe, Russia, CIS and Asia to Cheplapharm

TOKYO, June 16, 2021 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced that Astellas and Cheplapharm Arzneimittel GmbH ("Cheplapharm") have enterd into an Asset Purchase Agreement, under which Astellas will transfer the Products Rights for five legacy products (the "Products") in certain countries of Europe, Russia, Commonwealth of Independent States (CIS)1 and Asia.

Once the transaction closes, Cheplapharm will take over the Products Rights from Astellas and sell them in certain countries of Europe, Russia, CIS and Asia. Astellas will work closely with Cheplapharm to enable a smooth transition.

(1) Purpose of Asset Purchase Agreement

The agreement is a part of Astellas' ongoing efforts to improve the quality and efficiency of operations so as to accommodate the rapidly changing business environment and achieve sustainable growth. Astellas will continue to strengthen our business presence in Europe, Russia, CIS, and Asia through optimization of resource allocation.

(2) Financial Terms of Asset Purchase Agreement

€95 million

(3) Schedule of Asset Purchase Agreement

June 15, 2021: Signing of the Asset Purchase Agreement

September 2021 or later: Closing of the transaction(tentative)

After closing of the transaction, the Products Rights for the Products will be transferred in each country.


(4) List of the Products

Products Name


Acute respiratory infections, Helicobacter pylori associated


diseases, such as gastritis and gastric ulcer, urogenital

infections and others


Gastro protector with antibacterial effect on H. pylori

Chronic and recurrent respiratory infections with the highest

activity towards H. influenzae. Infections caused by


susceptible bacteria, such as urinary tract infections and

others, e.g. skin, secondary infection in trauma, burn or

surgical wound, cholangitis

Infections, such as mild community acquired pneumonia,


acute exacerbations of chronic bronchitis, lymphogranuloma

venereum, acne vulgaris, chlamydia trachomatis infections,

prostatitis, cervicitis and pelvic inflammatory diseases

Infections caused by gram-positive organisms (except MRSA


and MRSE), including infections caused by beta-lactamase

producing staphylococci

(5) Sales of the Products

€81.5 million(fiscal year ended March 31, 2021)

Astellas has already reflected the impact from this transaction in its financial forecast of the current fiscal year ending March 31, 2022.

  1. Commonwealth of Independent States (CIS): loose confederation of independent states consisting of the former Union of Soviet Socialist Republics.

About Astellas

Astellas Pharma Inc. is a pharmaceutical company conducting business in more than 70 countries around the world. We are promoting the Focus Area Approach that is designed to identify opportunities for the continuous creation of new drugs to address diseases with high unmet medical needs by focusing on Biology and Modality. Furthermore, we are also looking beyond our foundational Rx focus to create Rx+® healthcare solutions that combine our expertise and knowledge with cutting-edge technology in different fields of external partners. Through these efforts, Astellas stands on the forefront of healthcare change to turn innovative science into value for patients. For more information, please visit our website at https://www.astellas.com/en.


About Cheplapharm

CHEPLAPHARM is a pharmaceutical company headquartered in Greifswald, Germany, offering branded and niche products in more than 120 countries worldwide. The family-owned company specializes in selected active substances and indications and focuses on an international buy-and-build strategy. Working closely with its business partners, CHEPLAPHARM achieves sustainable annual growth rates. CHEPLAPHARM has been one of the fastest-growing pharmaceutical companies in Europe.

Please refer to www.cheplapharm.com for additional information.

Press office:

CHEPLAPHARM Arzneimittel GmbH ǀ Ziegelhof 24 ǀ 17489 Greifswald ǀ presse(at)cheplapharm.com

Cautionary Notes

In this press release, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on management's current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas' intellectual property rights by third parties.

Information about pharmaceutical products (including products currently in development) which is included in this press release is not intended to constitute an advertisement or medical advice.


Contacts for inquiries or additional information:

Astellas Pharma Inc.

Corporate Advocacy & Relations

TEL: +81-3-3244-3201



Astellas Pharma Inc. published this content on 16 June 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 16 June 2021 08:17:00 UTC.

© Publicnow 2021
07/20The U.S. Food and Drug Administration Approves Astellas Pharma Inc.'s Supplem..
07/15Piers Morgan rejoint le Conseil d'Administration de Pharnext
07/15Piers Morgan Joins Pharnext's Board of Directors
07/13ExCellThera and Astellas Enters into a License for the Use of Molecule UM171 ..
07/12Affinivax and Astellas Presents Safety and Immunogenicity Data from Phase 2 S..
07/12ASTELLAS PHARMA : U.S. FDA Grants Regular Approval and Expands Indication for PA..
07/11ASTELLAS PHARMA : U.S. FDA Grants Regular Approval and Expands Indication for PA..
07/09ASTELLAS PHARMA : U.S. FDA Grants Regular Approval and Expands Indication for PA..
06/29ASTELLAS PHARMA : Corporate Governance Report
06/28ASTELLAS PHARMA : Receives Positive CHMP Opinion for EVRENZO (roxadustat) for Ad..
More news
Sales 2022 1 320 B 11 935 M 11 935 M
Net income 2022 204 B 1 845 M 1 845 M
Net cash 2022 425 B 3 840 M 3 840 M
P/E ratio 2022 17,3x
Yield 2022 2,55%
Capitalization 3 543 B 32 055 M 32 043 M
EV / Sales 2022 2,36x
EV / Sales 2023 2,07x
Nbr of Employees 15 455
Free-Float 99,0%
Duration : Period :
Astellas Pharma Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTELLAS PHARMA INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 14
Last Close Price 1 912,00 JPY
Average target price 2 470,77 JPY
Spread / Average Target 29,2%
EPS Revisions
Managers and Directors
Kenji Yasukawa President, CEO & Representative Director
Yoshihiko Hatanaka Chairman
Yoshitsugu Shitaka Chief Scientific Officer
Fumiaki Sakurai Head-Business Administration & Compliance
Mamoru Sekiyama Independent Outside Director
Sector and Competitors
1st jan.Capi. (M$)
JOHNSON & JOHNSON9.16%432 430
ROCHE HOLDING AG12.39%325 975
PFIZER, INC.13.23%218 198
NOVARTIS AG1.10%207 246